Metrics as of 10/17/2026, 08:43 AM (Berlin time), refresh in progress.
Inovio Pharmaceuticals Stock
Inovio Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jacqueline E. Shea
- Employees
- 112
- Market cap
- $68 M
- IPO
- 08/12/1998
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA…
Inovio Pharmaceuticals stock: price history
1D
-4.8%
1W
-13.9%
1M
-13.9%
6M
-16.8%
YTD
-43.1%
1Y
-59.8%
2Y
-82.8%
5Y
-98.8%
10Y
-99.0%
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~2% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Inovio Pharmaceuticals
Analyst assessment of Inovio Pharmaceuticals
PRICE TARGET LOW
US$2.50
CONSENSUS
US$2.75
MEDIAN
US$2.75
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
10
BUY
5
HOLD
2
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 13/08/2026
Inovio Pharmaceuticals stock metrics
P/E
-0.85
P/B
18.49
EV/EBITDA
-0.7
RETURN ON EQUITY
-137.6%
NET MARGIN
0.0%
DEBT/EQUITY
1.83
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
118.5%
FLOAT SHARES
81,883,262
AVG. DAILY VOLUME (30D)
2,871,255
Insider transactions (SEC)
KIES PETER
KIES PETER
Humeau Laurent
Humeau Laurent
Shea Jacqueline Elizabeth
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Inovio Pharmaceuticals stock
What does Inovio Pharmaceuticals do?
Inovio Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jacqueline E. Shea, the company employs around 112 people.
The IPO was on 08/12/1998; the stock trades on NASDAQ under the ticker INO.
What do analysts say about Inovio Pharmaceuticals stock?
17 analysts rate the stock, the consensus is Buy (as of 13/08/2026).
The average price target is US$2.75, ranging from US$2.50 to US$3.00, with a median of US$2.75.
This is an external assessment, not a statement by Market Jury.
When does Inovio Pharmaceuticals report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does Inovio Pharmaceuticals pay a dividend?
Yes. The last dividend was US$0.01 per share, ex-date 28/09/2017, paid on 16/10/2017.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Inovio Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Inovio Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Inovio Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.